# a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Source: https://onco.cc/trials/nct04776330/  
OnCo record `nct04776330` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BCMA targeted prime CAR-T cells in multiple myeloma, run by Chongqing Precision Biotech Co., Ltd, now recruiting.

## Summary

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease is a phase 1/2 interventional study registered as NCT04776330 by Chongqing Precision Biotech Co., Ltd, with 80 participants planned, started 2021-03-07 and due to reach its primary completion in 2026-12-31. Interventions recorded: BCMA targeted prime CAR-T cells.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04776330
- Phase: 1/2
- Setting: Study Evaluating Safety and Efficacy of BCMA-Targeted Prime CAR-T Cell in Patients With Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
- Sponsor: Chongqing Precision Biotech Co., Ltd
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT04776330: https://clinicaltrials.gov/study/NCT04776330

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [Chongqing Precision Biotech](https://onco.cc/companies/chongqing-precision-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct04776330.json